| HOME >> BIOLOGY >> TECHNOLOGY |
ROCKVILLE, Md., Sept. 1, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that President and CEO Richard Garr will present at the 2011 Stifel Nicolaus Annual Healthcare Conference on Wednesday, September 7 at 8:00 a.m. EDT. Garr will discuss the Company's opportunities and advancements in neural stem cell pharmaceuticals and cellular therapy, and will be providing an update on the ongoing ALS trial at Emory University.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)
Garr will also present at the 2011 Rodman & Renshaw Annual Healthcare Conference on Tuesday, September 13 at 10:50 a.m. EDT.
The 2011 Stifel Nicolaus Annual Healthcare Conference will be held at the Four Seasons Hotel in Boston, September 7-9. For more information, see: www.stifel.com or http://www.tweisel.com/Stifel/ConferencesAndEvents/ .
The 2011 Rodman & Renshaw Annual Healthcare Conference will be held at The Waldorf=Astoria in New York City, September 11-13. For more information, see: http://www.rodmanandrenshaw.com/conferences?id=162 .
About Neuralstem
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major ce
'/>"/>
| SOURCE Neuralstem, Inc. Copyright©2010 PR Newswire. All rights reserved |